PubMed Health⌕ Search

Biomedical subjects

Y Ostchega

Publications and source records attributed to Y Ostchega.

25 records · Page 2Linked to original sources
PubMed1985

High-dose cisplatin in hypertonic saline in refractory ovarian cancer.

Nineteen previously treated refractory ovarian cancer patients, including 17 who had received standard-dose cisplatin regimens, were treated in a phase II trial with high-dose cisplatin (40 mg/m2 daily for five days with cycles administered every 28 to 35 days). Objective responses were achieved in 6/19 (32%) patients while eight patients had minor responses or stable disease. The median duration of survival from the start of salvage chemotherapy was 12 months for all patients, and 16 months for responding patients. The dose-limiting toxicity was peripheral neuropathy with 37% of patients having severe paresthesias or ataxia. These results indicate that the dose of cisplatin may be an important factor in improving survival in ovarian cancer patients.

Adult↗
PubMed1984

High-dose cisplatin in hypertonic saline.

To overcome the dose limiting toxicity of cisplatin we have administered high-dose cisplatin (200 mg/m2 body surface area in five divided daily doses with each dose administered in 250 mL of 3% saline) together with extensive hydration (250 mL/h normal saline with 20 meq KCI/L). In 17 previously untreated patients with poor prognosis nonseminomatous testicular cancer, 8 with tumor-associated obstructive uropathy, there was no statistically significant decrease in creatinine clearance or elevation of serum creatinine after three to four cycles of a high-dose cisplatin in combination chemotherapy regimen. High-dose cisplatin in combination with vinblastine, bleomycin, and VP-16 produced an 88% complete response rate in these high-risk patients who are characterized primarily by the presence of advanced bulky lung and abdominal disease. Six patients with ovarian cancer who had a relapse after treatment with standard dose cisplatin regimens were treated with high-dose cisplatin and three partial responses were seen. Four patients had no adverse effects on renal function whereas 2 patients had transient elevations in serum creatinine (4 to 5 mg/dL). Hypertonic saline did not provide protection against the nonrenal toxicities of cisplatin.

Adolescent↗
PubMed1982

Effects of cancer and its treatments on plasma concentration of alpha 1-acid glycoprotein and propranolol binding.

The plasma concentrations of alpha 1-acid glycoprotein (AAG) and albumin, and the plasma protein binding of propranolol were measured in a group of cancer patients and a group of normal subjects. In cancer patients the AAG concentrations were twice that in controls (142 and 78 mg/dl, P less than 0.005), the albumin concentrations were lower (3.11 and 4.37 gm/dl, P less than 0.001), and the free fraction of propranolol was lower (0.127 and 0.190, P less than 0.005). Propranolol binding correlated strongly with AAG concentrations. These data imply that untreated or unsuccessfully treated cancer patients will have reduced free fractions for any drug for which AAG is an important binding protein. Successfully treated patients may have longitudinal changes towards normal. No consistent effect of the treatments themselves on AAG was observed after radiation therapy in five patients or after intravenous adriamycin in six patients.

Adolescent↗
PubMedDate not supplied

MVP (mitomycin, vinblastine, and progesterone): a second-line regimen in ovarian cancer with a high incidence of pulmonary toxicity.

Thirteen patients with epithelial ovarian cancer refractory to primary combination chemotherapy regimens were treated with a three-drug combination called MVP: mitomycin, vinblastine, and progesterone. None of the patients had an objective response to therapy. Five of the 13 patients (39%) developed signs and symptoms consistent with drug-induced pulmonary toxicity following therapy with MVP and histologic confirmation was obtained in two patients. Mitomycin and vinblastine therapy in heavily treated patients with ovarian cancer may be associated with a higher risk of pulmonary toxicity than that previously reported for patients with other tumors.

Antineoplastic Agents↗